NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $692,199 | +24.1% | 88,066 | +57.7% | 0.02% | +13.3% |
| Q2 2023 | $557,981 | +80.8% | 55,854 | +60.7% | 0.02% | +87.5% |
| Q1 2023 | $308,553 | +3.9% | 34,747 | +28.5% | 0.01% | 0.0% |
| Q4 2022 | $297,009 | -8.9% | 27,050 | +8.3% | 0.01% | -27.3% |
| Q3 2022 | $326,000 | +148.9% | 24,986 | +141.4% | 0.01% | +83.3% |
| Q2 2022 | $131,000 | -78.9% | 10,350 | -76.7% | 0.01% | -79.3% |
| Q1 2022 | $621,000 | +9.3% | 44,328 | +125.8% | 0.03% | -17.1% |
| Q4 2021 | $568,000 | +47.9% | 19,632 | +59.1% | 0.04% | 0.0% |
| Q1 2021 | $384,000 | – | 12,337 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |